drugset / Trial / NCT07041801

Treatment of Systemic Lupus Erythematosus With Human Umbilical Cord Mesenchymal Stem Cells

NCT07041801

Phase 1/2 Recruiting 58 enrolled Shenzhen Beike Bio-Technology Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will investigate the safety and efficacy of allogeneic umbilical cord-derived stem cell therapy in treating patients with moderate to severe systemic lupus erythematosus.

Timeline

Start
2025-06-28
Primary completion
2027-09-05
Completion
2027-12-28

Drugs

EvaluationDrugModalityDoseRoute
Subject human umbilical cord mesenchymal stem cells Cell therapy 1e+06 cells/kg
Subject human umbilical cord mesenchymal stem cells Cell therapy 3e+06 cells/kg
Subject human umbilical cord mesenchymal stem cells Cell therapy 5e+06 cells/kg